Roth Capital began coverage on shares of Verastem (NASDAQ:VSTM) in a research report released on Friday morning. The firm issued a buy rating and a $12.00 target price on the biopharmaceutical company’s stock.
Several other brokerages also recently weighed in on VSTM. Zacks Investment Research upgraded Verastem from a sell rating to a hold rating in a report on Wednesday, November 8th. Cantor Fitzgerald set a $17.00 price target on Verastem and gave the company a buy rating in a report on Tuesday, October 31st. Oppenheimer reiterated a buy rating and issued a $6.00 price target on shares of Verastem in a report on Wednesday, September 6th. ValuEngine downgraded Verastem from a hold rating to a sell rating in a report on Friday, September 1st. Finally, HC Wainwright reiterated a buy rating and issued a $10.00 price target (up from $6.50) on shares of Verastem in a report on Thursday, September 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $7.78.
Verastem (NASDAQ:VSTM) opened at $3.84 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.12 and a current ratio of 3.12. Verastem has a 12-month low of $1.05 and a 12-month high of $5.71.
Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.29). sell-side analysts anticipate that Verastem will post -1.74 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP grew its stake in shares of Verastem by 137.1% during the 3rd quarter. Susquehanna International Group LLP now owns 75,526 shares of the biopharmaceutical company’s stock valued at $355,000 after buying an additional 43,675 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Verastem during the 3rd quarter valued at $136,000. Point72 Asset Management L.P. purchased a new stake in shares of Verastem during the 3rd quarter valued at $6,580,000. Dimensional Fund Advisors LP grew its stake in shares of Verastem by 93.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 561,969 shares of the biopharmaceutical company’s stock valued at $2,641,000 after buying an additional 272,141 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in shares of Verastem during the 3rd quarter valued at $195,000. Institutional investors own 34.24% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Roth Capital Initiates Coverage on Verastem (VSTM)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2017/12/05/roth-capital-initiates-coverage-on-verastem-vstm.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.